POOLBEG PHARMA

Investment Profile

1 **Rapidly growing pipeline**
Several new assets post IPO
Expansion & diversification of portfolio – reducing risk & increasing upside potential

2 **Unique capital light model**
1. Generate early human efficacy data
2. Rapidly monetise through partnering & licencing deals with pharma / biotech

3 **Well capitalised**
£20.9m at 31 Dec 2021
Low cash burn & long cash runway
Exploring non-dilutive grant funding

4 **POLB 001 trial starts June 22**
Study results H2 2022
Plans to rapidly monetise thereafter

5 **Booming infectious disease market**
Expected >$250bn by 2025
Pharma & biotech seeking products to in-licence

6 **Breakthrough AI Programme**
First time artificial intelligence used to identify drug targets using unique human challenge trial disease progression data

Investment Profile

Poolbeg Pharma (AIM:POLB, OTCQB:POLBF) is a clinical stage infectious disease pharmaceutical company, with a capital light clinical model which aims to develop multiple products faster and more cost effectively than the conventional biotech model. The Company, headquartered in London, is led by a team with a track record of creation and delivery of shareholder value and aspires to become a "one-stop shop" for Big Pharma seeking mid-stage products to license or acquire.

The Company is targeting the growing infectious disease market. In the wake of the COVID-19 pandemic, infectious disease has become one of the fastest growing pharma markets and is expected to exceed $250bn by 2025.

With its initial assets from Open Orphan plc, an industry leading infectious disease and human challenge trials business, Poolbeg has access to knowledge, experience, and clinical data from over 20 years of human challenge trials. The Company is using these insights to acquire new assets as well as reposition clinical stage products, reducing spend and risk. Amongst its portfolio of exciting assets, Poolbeg has a small molecule immunomodulator for severe influenza (POLB 001); a first-in-class, intranasally administered RNA-based immunotherapy for respiratory virus infections (POLB 002); and a vaccine for Melioidosis (POLB 003). The Company is also developing an oral vaccine delivery platform and is progressing two artificial intelligence (AI) drug discovery programmes to accelerate the power of its human challenge model data and biobank.

Share Price Information

| Ticker	POLB
Shares in Issue	500m
Market Cap (25 May 22)	£30m

Major Shareholders

Schroder Investment Management	5.13%
Cathal Friel, Co-founder & Chairman	7%

Unique Capital Light Model

Rapid Development & Frequent Out-Licencing
Developing multiple assets at once – reducing risk

1. Low cost clinical trials (£4-5m per asset)
2. Early human efficacy data (12-18 months)
3. Monetise by partnering with pharma & biotech
4. Funds reinvested into pipeline

Model enhances investor returns & expands runway

Recent infectious disease deals

Increased in-licencing deals by Big Pharma & biotech

Pfizer acquire ReViral
up to $525m, April 2022
Respiratory Syncytial Virus (RSV)

Bav Nordic licence Chinese rights to Nuance Pharma
$12.5M + $200M. Mar 2022
RSV

Merck acquired Oncoimmune
$425m upfront, Nov 2020
COVID-19

Pfizer's Valneva deal,
$130m upfront
+ $188m follow-on, April 2020
Lyme Disease

POOLBEG PHARMA

Rapidly Expanding pipeline of assets developed in-line with capital light model

Product pipeline

Product Candidate	Program	PreClinical	Phase 1	Phase 2	Phase 3
POLB 001	Severe Influenza treatment	LPS study data expected H2 '22		Monetisation Zone	
POLB 002	Respiratory virus infections treatment & prophylactic	➤			
POLB 003	Melioidosis vaccine*	➤			

Drug Discovery Platforms

Artificial Intelligence Drug Discovery Programme *Influenza* CytoReason	Artificial Intelligence Drug Discovery Programme *Respiratory Syncytial Virus* ONE THREE BIOTECH	Oral Vaccine Delivery Platform *Developing vaccines for multiple indications*	Vaccine Discovery Platform *Identify vaccine candidates from naturally occurring immune response*	PredictViral™ *Identify patients at risk of developing severe disease early*
1st Data - H1 2023	1st Data - H2 2022			

In active discussions for a range of other assets

■ Pre-IPO ■ Post-IPO *Reviewing 5 additional bacterial vaccine candidates from UCD

POLB 001 – treatment for severe influenza

1. **Human challenge trial to commence June 22**
2. **Early human efficacy data expected - H2 22**
3. **Plan for early monetisation thereafter**

- Trial to gather broad dataset - increase value
- Patent protected until 2038, expanding IP
- Potential peak sales $275m+ with label extensions
- Worldwide rights for all uses in humans
- Exploring further disease indications – increase value

POLB 001's ability to interrupt the feedback loop of inflammatory mediators that result in a 'cytokine storm' make it an ideal candidate to reduce disease severity for those most at risk

To simulate hyperinflammatory conditions, immune cells were treated with IL-6 and TNF-α, and IL-8 was used as a marker to measure resulting inflammation. The addition of POLB 001 reversed the inflammatory response in a dose dependent manner.

Key Upcoming Milestones

POLB 001
LPS challenge study data expected before year end 2022 – monetisation commences

POLB 002
Development plan underway

POLB 003
Complete in-licence & evaluation of 5 other vaccine programs

Oral Vaccine Delivery Platform - Development plan underway

RSV AI Drug Programme - Outputs expected in H2 2022

Influenza AI Drug Programme - Outputs expected in H1 2023

Non-dilutive funding - Applications progressing

IP Portfolio - Continuing to expand & strengthen

Stay in touch

www.PoolbegPharma.com
IR@PoolbegPharma.com
+44 207 183 1499

🐦 @PoolbegPharma

in Poolbeg Pharma

Sign up for RNS alerts